<DOC>
	<DOC>NCT02279602</DOC>
	<brief_summary>Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.</brief_summary>
	<brief_title>Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study</brief_title>
	<detailed_description>Subjects enrolled in the PNET/GI-NET study OX4218s received weekly dosing with fosbretabulin for up to 3 cycles or approximately 9 weeks. Subjects achieving a clinical response with a biomarker reduction or symptom response based on investigator assessment are eligible to enroll in this rollover study (protocol OX4219s). Subjects will receive fosbretabulin every three weeks for a maximum of approximately one year or until disease progression, unacceptable toxicity, consent withdrawal, protocol-noncompliance, or the investigator feels that it is no longer in the subject's best interest to continue therapy.</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>Subject has been treated in the OXiGENEsponsored Phase 2 study OX4218s Subject has not received fosbretabulin treatment in the study OX4218s</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Gastrointestional</keyword>
</DOC>